EBIT: Income before interest and taxes.
Rein Therapeutics Inc. (RNTX) had EBIT of $-32.66M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-31.97M |
|
-- |
|
-- |
|
$32.66M |
|
$-32.66M |
|
$-0.02M |
|
$-32.68M |
|
$-32.68M |
|
$-31.97M |
|
$-31.97M |
|
$-31.97M |
|
$-31.97M |
|
|
EBIT |
$-32.66M |
$-3.96M |
|
25.45M |
|
25.45M |
|
$-1.22 |
|
$-1.22 |
|
| Balance Sheet Financials | |
$4.33M |
|
-- |
|
$19.83M |
|
$24.16M |
|
$6.18M |
|
-- |
|
$46.06M |
|
$52.24M |
|
$-28.09M |
|
$-47.92M |
|
$-28.09M |
|
27.55M |
|
| Cash Flow Statement Financials | |
$-19.36M |
|
-- |
|
$9.76M |
|
$12.87M |
|
$3.21M |
|
$-9.65M |
|
$2.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.36M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
113.81% |
|
66.71% |
|
-132.32% |
|
113.81% |
|
$-1.02 |
|
$-0.76 |
|
$-0.76 |
|